Radiation therapy for extrahepatic bile duct cancer: Current evidences and future perspectives

Table 3 Stereotactic body radiotherapy for hilar cholangiocarcinoma

Ref.	Study period	Study design	No. of pts	RT dose	RT modality	Late toxicity ≥ Gr 3	Median OS (mo)
Kopek et al[51]1	1999-2006	Retrospective	27	45 Gy/3fx	linear accelerator	22.2% (duodenal ulcer)	10.62
Momm et al[52]	1998-2008	Retrospective	13	32-56 Gy/8-16fx	linear accelerator	None	33.53
Polistina et al[53]	2004-2009	Retrospective	10	30 Gy/3fx	Cyber Knife	None	35.53

¹Includes intrahepatic cholangiocarcinoma as well (3.7%);

²from the date of radiotherapy initiation;

³From the date of cancer diagnosis.